Skip to main content
S&P 5007,611.15+0.34%DOW52,061.59-0.06%NASDAQ26,162.26+0.70%BTC$76,078.00-0.98%ETH$2,408.58-1.03%GOLD$4,370.50+0.87%OIL$102.27-3.36%
Smart Investors Daily
NN

AMEX · NNVC

NanoViricides, Inc.

Healthcare · Biotechnology

$1.05

Up+$0.12 (+11.43%)

Updated Sep 16, 2026, 6:16 PM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
23.05M
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.87 – $1.93
Volume
752.04K
Avg. volume
305.78K

Price performance

NNVC price history

1M range · 0 trading sessions · Daily adjusted prices

NNVC does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest NNVC news

The latest Smart Investors Daily articles mentioning NNVC.

Stock researchCompany · Overview

NNVC research

Overview

Company profile and research snapshot.

Company profile

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
NNVC recent ratings
DateFirmRatingTarget
Jul 6, 2026Noble Capital MarketsOutperform—
May 7, 2024EF HuttonBuy—
Feb 16, 2024EF HuttonBuy—
Apr 18, 2023EF HuttonBuy—
Feb 28, 2023EF HuttonBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo

SHELTON, CT / ACCESS Newswire / September 8, 2026 / , Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo ("DRC") was successfully registered in the Pan African Clinical Trials Registry (pactr.

Yahoo · Aug 31, 2026

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles

SHELTON, CT / ACCESS Newswire / August 31, 2026 / , Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, provides an update on its Measles Drug Treatment Program.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By